Expression and Antibody Preparation of Glypican3

Abstract

Abstract: Human glypican3 protein is a potential cancer therapeutic targets and diagnostic markers. In order to obtain anti-GPC3 monoclonal antibody, GPC3 gene was cloned into an expression vector pGEX-2T, which was transformed into E. coli BL21(DE3). Induced by IPTG, a molecular weight of 58 kD protein was obtained. After immunizing BALB/c mice, cell fusion and screening, one monoclonal antibody was generated. Western blot analysis revealed that the antibody has a strong specificity and high titer can be used for GPC3 protein function and applied research.

Key words: Glypican-3, Protein expression, Monoclonal antibody

Cheng Hua, Fang Xiangdong, Wu Meng, Shi Lei, Cui Shuo. Expression and Antibody Preparation of Glypican3[J]. Biotechnology Bulletin, 2014, 0(3): 177-181.

References

[1] Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome[J]. Nat Genet, 1996, 12(3):241-247.
[2] Huber R, Crisponi L, Mazzarella R, et al. Analysis of exon/intron structure and 400 kb of genomic sequence surrounding the 5'-promoter and 3'-terminal ends of the human glypican 3(GPC3)gene[J]. Genomics, 1997, 45(1):48-58.
[3] Huber R, Mazzarella R, Chen CN, et al. Glypican 3 and glypican 4 are juxtaposed in Xq26.1[J]. Gene, 1998, 225(1-2):9-16.
[4] Veugelers M, De Cat B, Ceulemans H, et al. Glypican-6, a new member of the glypican family of cell surface heparan sulfate proteoglycans[J]. J Biol Chem, 1999, 274(38):26968-77.
[5] Filmus J. Glypicans:proteoglycans with a surprise[J]. Glycobiol-ogy, 2001, 11(3):19-23
[6] Shirakawa H, Kuronuma T, Nishimura Y, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer[J]. Int J Oncol, 2009, 34(3):649-56.
[7] Yasuda E, Kumada T, Toyoda H, et al. Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Gly-pican-3(GPC3)antibody, as a serological and histological marker for hepatocellular carcinoma[J]. Hepatol Res, 2010, 40(5):477-485.
[8] Shirakawa H, Suzuki H, Shimomura M, et al.Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma[J]. Cancer Sci, 2009, 100(8):1403-1407.
[9] Tangkijvanich P, Chanmee T, Komtong S, et al. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers[J]. J Gastroenterol Hepatol, 2010, 25(1):129-37.
[10] Filmus J, Capurro M. Glypican-3:a marker and a therapeutic target in hepatocellular carcinoma[J]. FEBS J, 2013, 280(10):2471-6.
[11] Benjamini E, Leskowitz S. Immunology, A Short Course[M].Second ed. New York:Wiley-Liss, Inc., 1991.
[12] 沈关心, 周汝麟. 现代免疫学实验技术[M].第2版, 武汉:湖北科学技术出版社, 2002:154-163.
[13] 萨姆布鲁克 J, 拉塞尔 DW. 分子克隆实验指南[M]. 黄培堂, 等译. 第3版, 北京:科学出版社, 2002:1713-1722.
[14] 吴孟超, 陈汉, 沈锋. 原发性肝癌的外科治疗—附5524例报告[J].中华外科杂志, 2001, 39(1):25-28.
[15] Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma:biological significance and temporospatial distribution[J]. Cancer Res, 1997, 57(22):5179- 5184.
[16] Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker[J]. Biochem Biophys Res Commun , 2003, 306:16-25.
[17] Capurro M, Wanless IR, Sherman M, et al. A novel serum and histochemical marker for hepatocellular carcinoma[J]. Gastroenterology, 2003, 125(1):89-97.